NDC 57664-419

Aspirin, Caffeine, and Dihydrocodeine Bitartrate

Aspirin, Caffeine, And Dihydrocodeine Bitartrate

Aspirin, Caffeine, and Dihydrocodeine Bitartrate is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Caraco Pharmaceutical Lab. The primary component is Aspirin; Caffei.

• Product ID: 57664-419_6f20cd49-8c5a-4349-9611-105bed7537a9
• NDC: 57664-419
• Product Type: Human Prescription Drug
• Proprietary Name: Aspirin, Caffeine, and Dihydrocodeine Bitartrate
• Generic Name: Aspirin, Caffeine, And Dihydrocodeine Bitartrate
• Dosage Form: Capsule
• Route of Administration: ORAL
• Marketing Start Date: 2012-10-01
• Marketing Category: NDA AUTHORIZED / NDA AUTHORIZED GENERIC
• Application Number: NDA011483
• Labeler Name: Caraco Pharmaceutical Lab
• Substance Name: ASPIRIN; CAFFEI
• Active Ingredient Strength: 356 mg/1; mg/1; mg/
• Pharm Classes: Cyclooxygenase
• DEA Schedule: CIII
• NDC Exclude Flag: E
• Listing Certified Through: 2018-12-31

Packaging

NDC 57664-419-88

100 CAPSULE in 1 BOTTLE (57664-419-88)

• Marketing Start Date: 2012-10-01
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 57664-419-88 [57664041988]

Aspirin, Caffeine, and Dihydrocodeine Bitartrate CAPSULE

• Marketing Category: NDA authorized generic
• Application Number: NDA011483
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2012-10-01
• Marketing End Date: 2018-05-31

Drug Details

Pharmacological Class

• Cyclooxygenase Inhibitors [MoA]
• Decreased Prostaglandin Production [PE]
• Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient]
• Nonsteroidal Anti-inflammatory Drug [EPC]
• Platelet Aggregation Inhibitor [EPC]
• Decreased Platelet Aggregation [PE]
• Central Nervous System Stimulant [EPC]
• Methylxanthine [EPC]
• Xanthines [CS]
• Central Nervous System Stimulation [PE]
• Full Opioid Agonists [MoA]
• Opioid Agonist [EPC]